Overview

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

This is a non-randomized, open-label, single-arm, multicenter, phase II study of palbociclib in combination with tamoxifen in women with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anticancer therapies for their advanced/metastatic disease.

Phase:

Phase 2

Details

Lead Sponsor:

Oana Danciu, MD

Collaborators:

Big Ten Cancer Research Consortium
Hoosier Cancer Research Network
Pfizer

Treatments:

Hormones
Palbociclib
Tamoxifen